Rubedo announces first-in-class drug candidate for dermatology
Rubedo Life Sciences has announced its development of a new drug candidate for dermatology, which they claim to be the first of its kind. The drug works by targeting a specific enzyme called GP73 that is found in high levels in the skin cells of patients with psoriasis, a chronic autoimmune disease that affects the skin. Rubedo’s drug candidate, named RLS-0071, is designed to inhibit the activity of GP73 and prevent the abnormal growth of skin cells that causes psoriasis. According to the company, RLS-0071 has shown promising results in pre-clinical studies and they are now preparing for clinical trials. The drug could potentially provide a new treatment option for the millions of people worldwide who suffer from psoriasis, which currently has limited treatment options.